We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case Report.
- Authors
TAKAHIRO HIRAI; MINEHIKO INOMATA; SHUHEI MINATOYAMA; MOE HASHIZUME; NAOKI TAKATA; KANA HAYASHI; ZENTA SETO; KOTARO TOKUI; CHIHIRO TAKA; SEISUKE OKAZAWA; KENTA KAMBARA; SHINGO IMANISHI; TOSHIRO MIWA; RYUJI HAYASHI; SHINICHI TANAKA; AKIRA NOGUCHI; TSUTOMU SATO
- Abstract
Background/Aim: Immune checkpoint inhibitors can induce immune-related adverse events in various organs, thus careful observation is required. Case Report: A 69-yearold man was diagnosed with advanced lung adenocarcinoma and treated with combined therapy of carboplatin plus pemetrexed plus pembrolizumab. After two cycles of treatment, anemia was noted. Myelosuppression due to cytotoxic anticancer agents was suspected and the cytotoxic agents were discontinued, followed by three courses of pembrolizumab monotherapy. However, the anemia persisted, requiring red blood cell transfusions. A bone marrow biopsy revealed erythroblast hypoplasia and chromosomal abnormalities, resulting in a diagnosis of pure red cell aplasia. These adverse events were considered immunerelated because of the treatment history with an immune checkpoint inhibitor, and 60 mg/day (1 mg/kg/day) of prednisolone was initiated. Anemia improved, and it did not recur during the tapering of prednisolone. Conclusion: Immune-related pure red cell aplasia should be considered for patients presenting anemia during treatment with immune checkpoint inhibitors.
- Subjects
PURE red cell aplasia; LUNG cancer; IMMUNE checkpoint inhibitors; CANCER treatment; PEMBROLIZUMAB
- Publication
In Vivo, 2024, Vol 38, Issue 3, p1509
- ISSN
0258-851X
- Publication type
Article
- DOI
10.21873/invivo.13599